Delivery Order SPE2DB24D9230-SPE2DB25FHVQL
- Not listed
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, valued at $10,222.72, is scheduled for completion by July 31, 2025, and was issued on July 30, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. This...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city....
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120 count). The contract, awarded on July 23, 2025, with a completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single-transaction fulfillment of pharmaceutical inventory...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, issued on July 22, 2025, is expected to be completed by July 23, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency on July 28, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a specific product requisition under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,017.54 on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award was issued under a firm fixed-price contract type with no set-aside designation, reflecting the company's competitive standing in federal procurement markets. The funding agency is the Defense Logistics Agency's Medical Supply Chain division, and...
- The Defense Logistics Agency awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (quantity: 120). This firm fixed-price delivery order, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a continuation of the ongoing pharmaceutical supply relationship between the agency and the vendor. The award carries no...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 30, 2025, for 120 tablets of Xtandi 40 mg with a ceiling value of $8,339.18. This firm fixed-price delivery order, which has an ultimate completion date of July 31, 2025, was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain. The award represents a single delivery order under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. This award was issued under DMS Pharmaceutical Group's larger Indefinite...
- SPE2DB24D9230Indefinite Delivery Contract
- SPE2DB24D9230-SPE2DB25FHVQLDelivery Order
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count packaging). This firm fixed-price delivery order, valued at $4,169.59, was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing delivery orders from the Defense Logistics Agency for branded and generic prescription medications, biologics, and medical consumables. Xtandi, an oncology treatment, represents one of the specialized pharmaceutical products within the company's contract portfolio. The company's status as a woman-owned small business, combined with its robust SAM.gov registration since 2001 and established distribution capabilities, positions it to effectively support the Department of Defense's healthcare supply requirements across military medical facilities nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 8/1/25 |